Karen L. MacKenzie

ProCanFDL uses federated deep learning to subtype cancers using proteomic data while preserving privacy, achieving performance gains over local models.

This study shows that combining EYA and PLK1 inhibitors is effective in treating neurological cancers by inducing cell death and targeting cancer stem cells.

The paper presents a pan-cancer proteomic map of 949 cell lines, revealing protein-specific biomarkers of cancer vulnerabilities and showing proteomic data's superior predictive power for drug response.